This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Acute Phase Proteins as Early Markers in Sepsis

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified March 2008 by University of Zurich.
Recruitment status was:  Not yet recruiting
Information provided by:
University of Zurich Identifier:
First received: March 17, 2008
Last updated: March 21, 2008
Last verified: March 2008

Monitoring of different serumproteins after severe trauma and during trauma-induced sepsis.

  • Trial with surgical intervention

Condition Intervention
Sepsis Procedure: No intervention

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Acute Phase Proteins as Early Markers in Sepsis

Resource links provided by NLM:

Further study details as provided by University of Zurich:

Estimated Enrollment: 15
Study Start Date: April 2008
Estimated Study Completion Date: September 2012
Intervention Details:
    Procedure: No intervention
    No intervention

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with severe trauma

Inclusion criteria:

  • Patients with severe trauma (ISS score > 16), both genders, patients on ICU

Exclusion criteria:

  • Moribund patients (pH <7,1, lactate >15mmol, Basedeficit > 15mEq/L, severe heart or liver injuries, GCS never over 5 after trauma)
  • Severe head injuries (AIS head >4)
  • Patient with severe infectious diseases, or diseases which severely affect the immune system (diabetes, Alkohol or nicotine abuse)
  • Non-german speaking patients
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00641355

Contact: 01 Studienregister MasterAdmins +41 (0)44 255 11 11

Not yet recruiting
Zurich, Switzerland
Sponsors and Collaborators
University of Zurich
Study Director: 01 Studienregister MasterAdmins UniversitaetsSpital Zuerich
  More Information

Responsible Party: PD Dr. Marius Keel, University Hospital of Zurich Identifier: NCT00641355     History of Changes
Other Study ID Numbers: StV 26-2007
Study First Received: March 17, 2008
Last Updated: March 21, 2008

Additional relevant MeSH terms:
Systemic Inflammatory Response Syndrome
Pathologic Processes processed this record on September 21, 2017